Advertisement
 
News
Subscribe to Drug Discovery & Development News

The Lead

Ivabradine Fast Tracked for Chronic HF

April 18, 2014 | Comments

The U.S. Food and Drug Administration (FDA) has granted fast track designation for investigational ivabradine - an oral drug that inhibits the If current (“funny” current) in the sinoatrial node, the body’s cardiac pacemaker - for patients with chronic heart failure (HF). Read more...

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Breaking News: Cubist Recalls Cubicin Lot

April 18, 2014 2:02 pm | Comments

Cubist Pharmaceuticals Inc. announced it is voluntarily recalling one lot of Cubicin (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles. Read more...

TOPICS:

New Pain Relief Targets Could Benefit Cancer Patients

April 18, 2014 12:36 pm | Comments

When researching how pain occurs in nerves in the periphery of the body, BBSRC-funded researchers at King's College London have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. Read more...

TOPICS:

Phase 1/2 Results Positive for Cancer Drug

April 18, 2014 12:20 pm | Comments

XBiotech is announcing that results from its Phase 1/2 oncology study conducted at MD Anderson Cancer Center in Houston, TX were published in Lancet Oncology, which describes the outcome in 52 advanced cancer patients treated with Xilonix, XBiotech’s anti-tumor therapy. Read more...

TOPICS:
Advertisement

Anti-Seizure Drug Could Reduce Alcohol Consumption

April 18, 2014 10:34 am | Comments

Researchers have discovered that the anti-seizure drug ezogabine, reduced alcohol consumption in an experimental model. The findings may lead to more effective treatments for alcoholism. Read more...               

TOPICS:

Actavis to Acquire New Products from Akorn

April 18, 2014 10:19 am | Comments

Actavis plc announced that it has entered into agreements with Akorn Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. Read more...         

TOPICS:

Multi-Target TB Drug May Treat Other Diseases, Evade Resistance

April 18, 2014 9:53 am | Comments

A drug under clinical trials to treat tuberculosis could be the basis for a class of broad-spectrum drugs that act against various bacteria, fungal infections and parasites, yet evade resistance, according to a new study. Read more...     

TOPICS:

Canada is First to Approve GSK's New COPD Drug

April 18, 2014 9:43 am | Comments

GlaxoSmithKline announced that Incruse Ellipta has received world-first market authorization in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD. Read more...       

TOPICS:

Canada is First to Approve GSK's New COPD Drug

April 18, 2014 9:43 am | Comments

GlaxoSmithKline announced that Incruse Ellipta has received world-first market authorization in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD. Read more...       

TOPICS:
Advertisement

Servier, Lab Founder in Drug Scandal, Dies at 92

April 18, 2014 9:17 am | Comments

Jacques Servier, the founder of France's second-largest pharmaceutical group who became ensnared in a scandal over a diabetes drug widely used for weight loss, has died. Read more...                   

TOPICS:

FDA OKs Merck Tablet to Reduce Ragweed Allergies

April 18, 2014 9:00 am | Comments

U.S. regulators have again approved Merck & Co.'s Ragwitek tablets, which dissolve quickly under the tongue, for gradually reducing seasonal allergies, this time for ragweed pollen. Read more...             

TOPICS:

NIH Awards Scripps $2M to Design a Better Diabetes Drug Model

April 17, 2014 1:21 pm | Comments

Scientists from the Florida campus of TSRI have been awarded $2.1 million from the NIH to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and CHF. Read more...

TOPICS:

Finding Suggests New Possibilities for Oncology and Virology

April 17, 2014 1:06 pm | Comments

Scientists at Washington University School of Medicine in St. Louis have uncovered a new way the immune system may fight cancers and viral infections, which could aid efforts to use immune cells to treat illness. Read more...     

TOPICS:

Sanguine, Mayo Clinic Agreement Furthers Personalized Medicine

April 17, 2014 12:40 pm | Comments

Sanguine announced an agreement with Mayo Clinic Bioservices, under which Mayo Clinic Bioservices will process, store and ship biospecimens that Sanguine has collected. Read more...                   

TOPICS:

New Gene Technology Has Therapeutic Implications

April 17, 2014 12:16 pm | Comments

For thousands of years humans have been tinkering with plant genetics, even when they didn’t realize that is what they were doing, in an effort to make stronger, healthier crops that endured climates better, and produced more. Read more...   

TOPICS:

VentiRx Completes Enrollment in Study of Orphan Cancer Drug

April 17, 2014 11:47 am | Comments

VentiRx Pharmaceuticals Inc. announced that enrollment has been completed in a Phase 2 trial of VTX-2337 in combination with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading